Medite Cancer Diagnostics (Medite Cancer Diagnostics) EPS (Diluted) : $-0.15 (TTM As of Sep. 2018)

Medite Cancer Diagnostics EPS (Diluted) Chart

Medite Cancer Diagnostics Annual Data
	Trend	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17
EPS (Diluted)		Get a 7-Day Free Trial					-	-0.04	-0.05	-0.11	-0.26

Medite Cancer Diagnostics Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
EPS (Diluted)	Get a 7-Day Free Trial															-0.06	-0.09	-0.04	-0.01	-0.01

Competitive Comparison of Medite Cancer Diagnostics's EPS (Diluted)

For the Medical Instruments & Supplies subindustry, Medite Cancer Diagnostics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medite Cancer Diagnostics's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medite Cancer Diagnostics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Medite Cancer Diagnostics's PE Ratio falls into.

Medite Cancer Diagnostics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Medite Cancer Diagnostics's Diluted EPS for the fiscal year that ended in Dec. 2017 is calculated as

Medite Cancer Diagnostics's Diluted EPS for the quarter that ended in Sep. 2018 is calculated as

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medite Cancer Diagnostics  (OTCPK:MDIT) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Medite Cancer Diagnostics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Medite Cancer Diagnostics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Medite Cancer Diagnostics (Medite Cancer Diagnostics) Business Description